Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Opexa Therapeutics

Opexa Therapeutics?uq=PEM9b6PF

Provider and developer of patient-specific cellular therapies intended for the treatment of autoimmune diseases. The company's personalized cellular immunotherapy treatment is in late stage clinical development targeting both Secondary Progressive and Relapsing Remitting MS, aligning the interests of patients, employees and shareholders.

Formerly Known As
Sportan United Industries, PharmaFrontiers
Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 2635 Technology Forest Boulevard
  • The Woodlands, TX 77381
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Opexa Therapeutics’s full profile, request a free trial.

Opexa Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 19-Sep-2017 000.00 Completed Profitable
9. 2PO 07-Aug-2013 0000 000.00 000.00 Completed Profitable
8. Loan 15-Feb-2013 00000 00.000 Completed Profitable
7. PIPE 16-Nov-2012 00.000 Completed Profitable
6. PIPE 00.000 Completed Profitable
5. Convertible Debt 01-May-2009 00.000 00.000 Completed Profitable
4. PIPE 13-Apr-2008 000 000 Completed Profitable
3. Accelerator/Incubator 01-Jan-2008 Completed Profitable
2. IPO 14-Apr-2004 Completed Profitable
1. Early Stage VC 01-Feb-2001 Completed Profitable
To view this company’s complete deal history including valuation and funding, request access »

Opexa Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
BCM Technologies Venture Capital Minority 000 0000 000000 0
Diker Management Hedge Fund Minority 000 0000 000000 0
Houston Technology Center Accelerator/Incubator Minority 000 0000 000000 0
Lehman Brothers Other Private Equity Minority 000 0000 000000 0
Lincoln Park Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »